Zydus Lifesciences Ltd 2017 AR2
The report highlights Cadila Healthcare Limited's operational and financial performance for the fiscal year 2016-17, including its Business Responsibility Report. Key achievements include the successful USFDA inspection of the Moraiya formulations facility without any 483 observations and the acquisition of Sentynl Therapeutics Inc. to enter the US specialty pain market. The company also launched over 75 new products in India and expanded its community outreach in education, healthcare, and skill development through the Ramanbhai Foundation.
Company: Zydus Lifesciences Ltd
Sector: Health Care
Country: India
Year: 2017
Type: AR2
Pages: 270
Zydus Lifesciences Ltd
Annual Report
The report highlights Cadila Healthcare Limited's operational and financial performance for the fiscal year 2016-17, including its Business Responsibility Report. Key achievements include the successful USFDA inspection of the Moraiya formulations facility without any 483 observations and the acquisition of Sentynl Therapeutics Inc. to enter the US specialty pain market. The company also launched over 75 new products in India and expanded its community outreach in education, healthcare, and skill development through the Ramanbhai Foundation.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Apr 1, 2016 - Mar 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees